WO1994016690A1 - Method for increasing the efficiency of feed conversion in animals - Google Patents
Method for increasing the efficiency of feed conversion in animals Download PDFInfo
- Publication number
- WO1994016690A1 WO1994016690A1 PCT/US1993/011093 US9311093W WO9416690A1 WO 1994016690 A1 WO1994016690 A1 WO 1994016690A1 US 9311093 W US9311093 W US 9311093W WO 9416690 A1 WO9416690 A1 WO 9416690A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cla
- feed
- animal
- fed
- efficiency
- Prior art date
Links
- 241001465754 Metazoa Species 0.000 title claims abstract description 44
- 238000000034 method Methods 0.000 title claims abstract description 18
- 238000006243 chemical reaction Methods 0.000 title claims description 16
- 230000001965 increasing effect Effects 0.000 title claims description 6
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims abstract description 96
- 229940108924 conjugated linoleic acid Drugs 0.000 claims abstract description 80
- JBYXPOFIGCOSSB-GOJKSUSPSA-N 9-cis,11-trans-octadecadienoic acid Chemical compound CCCCCC\C=C\C=C/CCCCCCCC(O)=O JBYXPOFIGCOSSB-GOJKSUSPSA-N 0.000 claims abstract description 79
- 235000019786 weight gain Nutrition 0.000 claims abstract description 20
- 230000004584 weight gain Effects 0.000 claims abstract description 14
- 230000002708 enhancing effect Effects 0.000 claims abstract description 8
- 230000037396 body weight Effects 0.000 claims description 21
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 19
- 235000020778 linoleic acid Nutrition 0.000 claims description 19
- 238000011065 in-situ storage Methods 0.000 claims 1
- 235000005911 diet Nutrition 0.000 description 31
- 230000037213 diet Effects 0.000 description 23
- 239000002158 endotoxin Substances 0.000 description 20
- 241000700159 Rattus Species 0.000 description 15
- 238000011282 treatment Methods 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 13
- 241000030538 Thecla Species 0.000 description 11
- 241000283973 Oryctolagus cuniculus Species 0.000 description 10
- 235000021050 feed intake Nutrition 0.000 description 10
- 235000013305 food Nutrition 0.000 description 10
- 231100000252 nontoxic Toxicity 0.000 description 9
- 230000003000 nontoxic effect Effects 0.000 description 9
- 235000020940 control diet Nutrition 0.000 description 8
- 230000000378 dietary effect Effects 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- GKJZMAHZJGSBKD-UHFFFAOYSA-N (10E,12E)-Octadeca-9,11-dienoic acid Natural products CCCCCC=CC=CCCCCCCCCC(O)=O GKJZMAHZJGSBKD-UHFFFAOYSA-N 0.000 description 7
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- GKJZMAHZJGSBKD-BLHCBFLLSA-N (10e,12e)-octadeca-10,12-dienoic acid Chemical compound CCCCC\C=C\C=C\CCCCCCCCC(O)=O GKJZMAHZJGSBKD-BLHCBFLLSA-N 0.000 description 6
- GKJZMAHZJGSBKD-ANYPYVPJSA-N 10-trans-12-cis-linoleic acid Natural products CCCCCC=C\C=C\CCCCCCCCC(O)=O GKJZMAHZJGSBKD-ANYPYVPJSA-N 0.000 description 6
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 5
- 241000287828 Gallus gallus Species 0.000 description 5
- 239000007995 HEPES buffer Substances 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 229920006008 lipopolysaccharide Polymers 0.000 description 5
- 102000000589 Interleukin-1 Human genes 0.000 description 4
- 108010002352 Interleukin-1 Proteins 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000006317 isomerization reaction Methods 0.000 description 4
- 244000144977 poultry Species 0.000 description 4
- 235000013594 poultry meat Nutrition 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 3
- JBYXPOFIGCOSSB-XBLVEGMJSA-N 9E,11E-octadecadienoic acid Chemical compound CCCCCC\C=C\C=C\CCCCCCCC(O)=O JBYXPOFIGCOSSB-XBLVEGMJSA-N 0.000 description 3
- 241000271566 Aves Species 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 241000700157 Rattus norvegicus Species 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 235000021323 fish oil Nutrition 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 235000014590 basal diet Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003240 coconut oil Substances 0.000 description 2
- 235000019864 coconut oil Nutrition 0.000 description 2
- 239000002285 corn oil Substances 0.000 description 2
- 235000005687 corn oil Nutrition 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 235000006486 human diet Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 239000008024 pharmaceutical diluent Substances 0.000 description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 241000273930 Brevoortia tyrannus Species 0.000 description 1
- 241000605900 Butyrivibrio fibrisolvens Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000004195 Isomerases Human genes 0.000 description 1
- 108090000769 Isomerases Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229910001854 alkali hydroxide Inorganic materials 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 235000019728 animal nutrition Nutrition 0.000 description 1
- 239000003005 anticarcinogenic agent Substances 0.000 description 1
- 238000006701 autoxidation reaction Methods 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 235000013367 dietary fats Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- JBYXPOFIGCOSSB-UHFFFAOYSA-N octadeca-9,11-dienoic acid Chemical class CCCCCCC=CC=CCCCCCCCC(O)=O JBYXPOFIGCOSSB-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 235000014059 processed cheese Nutrition 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000004767 rumen Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
- A23C9/1315—Non-milk proteins or fats; Seeds, pulses, cereals or soja; Fatty acids, phospholipids, mono- or diglycerides or derivatives therefrom; Egg products
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/158—Fatty acids; Fats; Products containing oils or fats
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/70—Feeding-stuffs specially adapted for particular animals for birds
- A23K50/75—Feeding-stuffs specially adapted for particular animals for birds for poultry
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/173—Reuteri
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Animal Husbandry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Biophysics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Fodder In General (AREA)
- Feed For Specific Animals (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A method of enhancing weight gain and feed efficiency in an animal which comprises administering to the animal a safe and effective amount of a conjugated linoleic acid.
Description
METHOD FOR INCREASING THE EFFICIENCY OF FEED CONVERSION IN ANIMALS
The present invention generally relates to animal nutrition. More particularly, it relates to a method of increasing the efficiency of feed conversion in an animal into body weight.
The efficiency of feed conversion into body weight varies significantly among different species of animals. Because feed is a relatively expensive cost factor in the production of food producing animals (50 to 70% of the cost of production) , any improvement in the ability of the animal to convert feed into food products can directly improve the profitability of a food producer. For example, an increase in the efficiency of feed conversion in broilers that results in a 1% increase in body weight for the same amount of feed could alone result in savings of over 85 million dollars for the U.S. broiler industry. In addition, there would be millions of dollars of savings because of reduced mortality and a reduction in the days required before marketing the broilers.
There is a need for a method of improving the ability of healthy meat animals to more efficiently convert their feed to body weight or other edible products.
There also is a need for a safe and effective method for increasing the body weight of animals, including
humanε, who for medical or other reasons can only consume a limited amount of food.
It is an object of the present invention to disclose a method of enhancing weight gain and feed efficiency in an animal.
We have discovered a method of enhancing weight gain and feed efficiency in an animal which comprises administering to said animal a weight gain enhancing and feed efficiency enhancing amount of a conjugated linoleic acid (CLA) selected from 9, 11-octadecadienoic acid; 10, 12-octadecadienoic acid; and mixtures thereof.
It will be apparent to those skilled in the art that the forementioned objects and other advantages may be achieved by the practice of the present invention. In a preferred embodiment of the method of the present invention the safe and effective amount of the conjugated linoleic acid, which is selected from 9,11- octadecadienoic acid; 10, 12-octadecadienoic acid and mixtures thereof, is added to the feed of an animal in which it is desired to enhance the efficiency of feed conversion and enhance body weight. The amount of the conjugated linoleic acid to be added to the animal's feed will vary with the species and size of the animal. However, since the conjugated linoleic acids are natural food ingredients and relatively non-toxic, the amount which can be administered is not critical as long as it is enough to be effective.
The practice of the present invention is further illustrated by the examples which follow: Example 1
Groups of one week old chicks were fed a standard control diet, or the diet supplemented with 0.5% CLA, or with 0.5% linoleic acid. Feed consumption and weight gain were closely monitored. After 1 week, the feed conversion (grams of feed required to produce 1 gram increase in weight gain) were as follows: group fed
control diet, 1.55 grams feed; group fed diet containing 0.5% CLA, 1.42 grams feed; group fed diet containing 0.5% linoleic acid, 1.56 grams feed. After 2 weeks, the feed conversions were: control group, 1.57 grams feed; group fed 0.5% CLA, 1.46 grams feed; group fed 0.5% linoleic acid, 1.53 grams feed. Clearly, when CLA was added to the diet, less feed was required to produce an equivalent weight gain. Hence, the CLA clearly improved the feed conversion efficiency of the animals. Example 2
Four pens of 10 chicks were fed a standard poultry ration with 0.5% lard (controls) or with 0.5% CLA mixed daily (2 pens per treatment) . When the chicks were 3 weeks of age, they were weighed and then injected with endotoxin. As seen in Table 1 the chicks fed the unsupplemented diet failed to gain body weight over the next 24 hours, whereas the chicks fed CLA gained up to 10 grams (p<.07) .
TABLE 1 A Avv.. Av. Wt. Av. % with no
Initial 24h post initial or negative
Treatment Wt. endotoxin 24h αain
Control 311 ± 12 311 ± 12 0 ± 3 53
.5% CLA 305 ± 9 315 ± 9 10 ± 4 27
Example 3
Another group of chicks were fed a diet containing 0.5% CLA which was mixed with the feed daily. At 3 weeks of age the chicks were inoculated i.p. with 750μg E. Coli 055:B5 endotoxin to stimulate immunity or phosphate buffered saline (PBS) as a control. The control chicks injected with PBS gained 9 g over the following 24h period, and the CLA fed, PBS injected chicks gained 13.5 g. When chicks fed the control diet were injected with endotoxin, they lost 1.3 g of body weight over the following 24h period. However, the CLA fed chicks even
after endotoxin injection continued to gain an average of 6.6 g.
The results of the examples demonstrate that a lower proportion of chicks lose weight, within 24 hours of being injected with endotoxin, when the chicks ingest feed which contains CLA. In fact, the results in Tables 2 and 3 show that not only do a fewer number of birds lose weight but that those birds that are fed CLA actually gain considerably more weight than the control birds. In addition, in other studies the loss of body weight in rats fed CLA following stimulation was found to be only 50% of those not fed CLA.
TABLE 2
Effect of feeding different levels of CLA to chicks1 on 24 hour body weight gain following endotoxin injection
Diet 24 hr gain ( Q) % neg. gain3 Control2 1.7 40%
0.3% 5.5 18%
1.0% 3.3 28% Total CLA 24 hr gain (g) % neg. gain
1.7 40%
+ 4.4 23%
'Chicks were fed CLA for 14 consecutive days prior to endotoxin injection. 2Diet analysis revealed trace amounts of CLA in control diet. Contamination was most likely from pig lard which was used as the dietary fat source.
3The number of chicks with a negative weight gain during the 24 hour period immediately following endotoxin challenge.
TABLE 3
Effect of feeding CLA1 to chicks for 3 or less days, or for more than 3 or more days2 prior to endotoxin challenge on 24 hour body weight gain.
Time Gain 24 hr % BW Feed consumed fed CLA post challenge change per chick3
>3 days -0.95 -0.32 13.17 g
<3 days -5.42 -2.08 9.56 g
'Chicks were fed 0.5% CLA in their diets. 2Greater than 3 days means up to 21 days.
3Feed consumed in the 24 hours post endotoxin challenge. Increased feed intake in this experiment equates with mitigation of illness from endotoxin challenge.
Example 4 A group of seven rats was fed a semi-purified diet containing 5% corn oil and .5% stearic acid; a second group was fed the same diet with corn oil but also containing added free linoleic acid (0.5%) . Three weeks later the animals were weighed. Four animals from each group were inoculated with endotoxin (1 mg/kg body weight) ; the remaining three animals from each group were inoculated with PBS. Rats fed the control diet and injected with PBS gained 7.4 g. Rats fed the diet to which linoleic acid had been added, and injected with PBS, gained 7.2 g. Rats fed control diet and injected with endotoxin lost 21.05 g. Rats fed diet to which linoleic acid had been added, and injected with endotoxin, lost only 11.4 g. These results are due to the conversion of added linoleic acid to CLA within the body of rats.
Example 5 To demonstrate the unique ability of CLA to increase the efficiency of rabbits to convert feed into body weight, the rabbits were fed food supplemented with CLA, linoleic acid, and oils. The amounts of the CLA, the linoleic acid and the oils administered and the results are shown in Tables 4 to 6.
TABLE 4
SEMI-SYNTHETIC DIET WITH 12° COCONUT OIL AND 2% CORN OIL
Food Body
Consumption Weight
(g) Gain (g)
1 53 -60 2 48 -180 3 29 -150 4 59 -230 5 42 -320
46g -200g (average) (average)
6 60 -150 7 44 -330 8 37 -100 9 36 -210 10 47 -270
TABLE 5
RABBITS #1-6 SWITCHED
TO SAME SEMI-SYNTHETIC
DIET SUPPLEMENTED
WITH 0.5% COCONUT OIL
# Food Body
Consumption Weight
(g) Gain (g)
1 54 0 2 46 -100 3 45 -140
4 64 -120 5 51 -170 6 54 -100
TABLE 6
RABBITS #7-10 SWITCHED
TO SAME SEMI-SYNTHETIC
DIET SUPPLEMENTED
WITH 0 . 5% CLA
# Food Body
Consumption Weight
(g) Gain (g)
7 53 +30
8 47 +30
49g +30g
) (average) } (average)
9 42 +50
10 55 +10
Example 6 Three groups of rabbits (4/group) were fed control chow diet, chow diet containing 1% CLA, or chow diet containing 1% linoleic acid. The animals were given 100 g of feed each day. During a 3-week period, the mean weight gain for these groups was as follows:
Rabbits fed control diet 35 g
Rabbits fed diet containing 1% CLA 132 g
Rabbits fed diet containing 1% linoleic acid . . 75 g
Clearly, the results show that CLA has a substantial positive effect on weight gain in these animals. The effect of CLA is greater than that observed with linoleic acid. During the 21-day time period, the CLA-fed rabbits ate 21 g CLA. Even if all of this CLA were retained as body fat, it would not account for the observed weight gain relative to controls (132g - 35g = 97g) .
Example 7 Three groups of 14 healthy chicks were fed a basal diet with 0 (control), .3, or 1% CLA. Pen feed conversion was determined weekly for 3 weeks. During all periods, 0 to 1 weeks, 0 to 2 weeks, 0 to 3 weeks of age on the dietary treatments, chicks fed CLA had marked improvements in the grams of feed needed to generate a gram of body weight (Table 7) . The results in Table 7 are similar to the results seen in rats, mice and rabbits.
TABLE 7
Feed intake (g) /Body weight gain (g)
Treatment 0-1 wk 0-2 wk control 2.53 2.62
.3% CLA 2.38 2.40
1% CLA 2.34 2.16
Example 8 Rats (7 per treatment) were individually caged and fed a diet containing .5% stearic acid, or .5% CLA for 4 weeks. Each week the amount (grams) of feed needed for gain (grams) was determined. Rats fed CLA consistently had better feed conversion than rats fed stearic acid (Table 8) .
TABLE 8
Feed intake (g) /Body weight gain (g) Treatment Wk 1 Wk 2 Wk 3 Wk 4
.5% stearate 2.98 2.90 3.34 3.57
.5% CLA 2.51 2.49 3.02 3.36
Example 9 Ten rats, individually caged, were fed a control diet (.5% stearate) or a diet containing .5% CLA for 1 week, 2 weeks, 3 weeks, or 4 weeks. Feed intake/gain was calculated for each period rats were fed CLA or stearate. Table 9 shows that rats fed CLA for 2, 3, or 4 weeks had a marked improvement in the grams of feed needed for a gram of gain.
TABLE 9
Feed intake (g) /Body weight gain (g)
Treatment Wk 1* Wk 2 Wk 3 Wk 4
.5% stearate 1.87 2.13 2.48 2.73 .5% CLA 1.85 1.58 2.11 2.64
'indicates the length of time the rats were fed CLA.
Example 10 Fourteen individually caged rats were assigned to each of 3 dietary treatments: Control (no CLA) , .3% CLA, and 1% CLA. The amount of feed (grams) needed for each gram of gain was determined each week for 2 weeks. Rats fed .3 or 1% CLA had a reduction in the grams of feed needed for each gram of gain (Table 10) .
TABLE 10
Feed intake (g) /Body weight gain (g) % CLA 0-1 Wk 1-2 Wk 0-2 Wk
0 2.74 2 . 68 2 . 71
.3 2.27 2 . 17 2 . 21
1.0 1.89 2 . 20 2 . 05
Example 11 Three-week old mixed sexed mice (5 groups of 4 mice per dietary treatment) were fed a diet containing no fatty acid addition, .5% fish menhaden oil, or .5% CLA. After 15 days of feeding 2 groups of mice per dietary treatment were injected ip with 1 mg E. coli 055:B5 lipopolysaccharide (LPS) in HEPES buffer, 1 group of mice per dietary treatment was injected ip with mouse interleukin-1 in HEPES buffer, and 2 groups of mice per dietary treatment were injected ip with only HEPES buffer. The percent change in feed consumed of mice injected with LPS or IL-1 relative to the HEPES injected mice within each dietary treatment was determined 24 hours after the injections. Table 11 shows that CLA-fed mice injected with LPS had less of a relative reduction in feed intake than mice fed fish oil or no fat inclusion. When the mice fed the various dietary treatments were injected with IL-1, those mice fed the basal diet had a 20% relative reduction in feed intake, while those fed CLA had an actual 10% increase in relative feed intake. The fish oil fed mice had intermediate intakes. These data suggest that CLA is
effective in preventing or reducing the negative effects immune stimulation has on feed intake.
TABLE 11
Consumption (24 hr) following immune stim. (% gain relative to HEPES injection)
Treatment IL-1 LPS
Basal -20.0 -96.3
.5% fish oil + 4.5 -95.1
.5% CLA +10.3 -27.5
The use of CLA in poultry feed improves the ability to convert feed, enhances growth and prevents weight loss in poultry. For broiler chickens alone, a decrease in feed/body weight of .01 could equal savings of $22 million/yr to the broiler industry. The difference between the conversion of the control and 1% CLA would thus be worth over $1 billion/yr.
In another embodiment of the invention, linoleic acid is administered to an animal which can convert the linoleic acid into CLA or which modulates the level of CLA in the body of an animal or a human. The linoleic acid is converted to CLA in the animal, probably by microorganisms in the animal's gastrointestinal system.
The method of the present invention may take other embodiments. For example, the CLA can be administered to an animal in a pharmaceutical or veterinary composition, such as tablets, capsules, solutions or emulsions, containing a safe and effective dose of the CLA.
The animal feeds and pharmaceutical preparations for use in the method of the present invention are those containing the active forms of the free conjugated linoleic acids (CLA) , especially 9, 11-octadecadienoic acid and 10,12-octadecadienoic acid or mixtures thereof in combination with a conventional animal feed (e.g.
poultry feed) , human food supplement, or an approved pharmaceutical diluent.
The active forms of CLA include, in addition to the free acids the active isomers of CLA; non-toxic salts thereof; active esters and other active chemical derivatives thereof; and mixtures thereof.
The free conjugated linoleic acids (CLA) have been previously isolated from fried meats and described as anticarcinogens. Since then, they have been found in some processed cheese products. However, animal feeds containing CLA, or its non-toxic derivatives, such as the sodium and potassium salts, as an additive in combination with conventional animal feeds or human foods are believed to be novel. The free acid forms of the CLA may be prepared by isomerizing linoleic acid. The non-toxic salts of the free CLA acids may be made by reacting the free acids with a non-toxic base. Natural CLA may also be prepared from linoleic acid by the action of an isomerase from a harmless microorganism such as the Rumen bacterium
Butyrivibrio fibrisolvens. Harmless microorganisms in the intestinal tracts of rats and other monogastric animals may also convert linoleic acid to CLA.
The CLA obtained by the practice of the described methods of preparation contains one or more of the 9,11- octadecadienoic acids and/or 10,12-octadecadienoic acids and active isomers thereof. It may be free or bound chemically through ester linkages. The CLA is heat stable and can be used as is, or dried and powdered. The CLA is readily converted into a non-toxic salt, such as the sodium or potassium salt, by reacting chemically equivalent amounts of the free acid with an alkali hydroxide at a pH of about 8 to 9.
Theoretically, 8 possible geometric isomers of 9,11- and 10, 12-octadecadienoic acid (c9,cll; c9,tll; t9,cll; t9,tll; cl0,cl2; cl0,tl2; tl0,cl2 and tl0,tl2) would form
from the isomerization of c9,cl2-octadecadienoic acid. As a result of the isomerization, only four isomers (c9,cll; c9,tll; tl0,cl2; and cl0,cl2) would be expected. However, of the four isomers, c9,tll- and tl0,cl2- isomers are predominantly produced during the autoxidation or alkali-isomerization of c9,cl2-linoleic acid due to the co-planar characteristics of 5 carbon atoms around a conjugated double-bond and spatial conflict of the resonance radical. The remaining two c,c-isomers are minor contributors.
The relatively higher distribution of the t,t- isomers of 9,11- or 10, 12-octadecadienoic acid apparently results from the further stabilization of c9,tll- or tlO,cl2-geometric isomers, which is thermodynamically preferred, during an extended processing time or long aging period. Additionally the t,t-isomer of 9,11- or 10, 12-octadecadienoic acid that was predominantly formed during the isomerization of linoleic acid geometrical isomers (t9,tl2-, c9,tl2- and t9,cl2-octadecadienoic acid) may influence the final ratio of the isomers or the final CLA content in the samples.
Linoleic acid geometrical isomers also influence the distribution of minor contributors (c,c-isomers of 9,11- and 10,12-, t9,cll- and ell,tl2-octadecadienoic acids) . The 11,13-isomer might be produced as a minor product from c9,cl2-octadecadienoic acid or from its isomeric forms during processing.
The exact amount of CLA to be administered, of course, depends upon the animal, the form of CLA employed, the route of administration, and extent of the increase in body weight desired.
Generally, the amount employed of CLA and its non-toxic salts employed as a pharmaceutical for humans will range from about 1,000 parts per million (ppm) to about 10,000 ppm of CLA of the human's diet. However, the upper limit of the amount to be employed is not
critical because CLA is relatively non-toxic and it is a normal constituent of the human diet (including human breast milk) .
The preferred pharmaceutical and veterinary composi- tions of CLA contain the non-toxic sodium or potassium salt of CLA in combination with a pharmaceutical diluent. When the compositions are solutions or suspensions intended for oral administration the diluent will be one or more diluents, such as lactose or starch, and the product will be a tablet, capsule or liquid. When the compositions are solutions or suspensions intended for parenteral administration the preferred diluent will be Sterile Water for Injection U.S.P.
The amount of CLA to be added to an animal's feed as an additive can range from .01% to 2.0% or more by weight of the animal's or human's food.
It will be readily apparent to those skilled in the art that a number of modifications or changes may be made without departing from the spirit and scope of the present invention. Therefore, the invention is only to be limited by the claims.
Claims
1. A method of enhancing weight gain and feed efficiency in an animal which comprises administering to the animal a weight gain enhancing and feed efficiency enhancing amount of a conjugated linoleic acid.
2. A method of claim 1 in which the animal is a bird.
3. A method of claim 1 in which the animal is a mamma1.
4. A method of increasing the efficiency of feed conversion in an animal which is capable of converting linoleic acid into CLA in situ, said method comprising administering to said animal a safe and effective amount of linoleic acid to increase the efficiency of feed conversion to body weight in said animal.
5. A method of improving the feed for an animal which comprises adding to said feed an amount of CLA which is effective to enhance weight gain and to increase the efficiency of feed conversion of said animal.
6. A feed of claim 5 in which the added amount of CLA is about 0.1% to about 2.0% of the weight of the feed.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP6516993A JP2745245B2 (en) | 1993-01-22 | 1993-11-16 | How to increase animal feeding efficiency |
DE69328497T DE69328497T2 (en) | 1993-01-22 | 1993-11-16 | METHOD FOR INCREASING THE EFFECTIVENESS OF ANIMAL FEEDING |
EP94902262A EP0680318B1 (en) | 1993-01-22 | 1993-11-16 | Method for increasing the efficiency of feed conversion in animals |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/007,413 | 1993-01-22 | ||
US08/007,413 US5428072A (en) | 1992-04-29 | 1993-01-22 | Method of increasing the efficiency of feed conversion in animals |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1994016690A1 true WO1994016690A1 (en) | 1994-08-04 |
Family
ID=21726009
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1993/011093 WO1994016690A1 (en) | 1993-01-22 | 1993-11-16 | Method for increasing the efficiency of feed conversion in animals |
Country Status (5)
Country | Link |
---|---|
US (1) | US5428072A (en) |
EP (1) | EP0680318B1 (en) |
JP (1) | JP2745245B2 (en) |
DE (1) | DE69328497T2 (en) |
WO (1) | WO1994016690A1 (en) |
Cited By (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996006605A1 (en) * | 1994-08-29 | 1996-03-07 | Wisconsin Alumni Research Foundation | Method of reducing body fat in animals by the administration of conjugated linoleic acid |
EP0779033A1 (en) * | 1995-11-14 | 1997-06-18 | Unilever N.V. | Edible fat-spread |
WO1997046230A1 (en) * | 1996-06-07 | 1997-12-11 | Wisconsin Alumni Research Foundation | Method for maintaining an existing level of body fat and/or body weight |
WO1998005319A1 (en) * | 1996-08-07 | 1998-02-12 | Wisconsin Alumni Research Foundation | Methods of preventing skeletal problems in poultry |
DE19718245C1 (en) * | 1997-04-30 | 1998-07-30 | Henkel Kgaa | Synthetic tri:glyceride(s) useful as food additives |
US5851572A (en) * | 1997-04-25 | 1998-12-22 | Wisconsin Alumni Research Foundation | Method of increasing fat firmness and improving meat quality in animals with conjugated linolenic acid |
WO1999012538A1 (en) * | 1997-09-05 | 1999-03-18 | Otsuka Pharmaceutical Co., Ltd. | Liver fat accumulation inhibitory composition, food additive for liver fat accumulation inhibition, and method of inhibiting liver fat accumulation |
WO1999020123A1 (en) * | 1997-10-21 | 1999-04-29 | Valio Oy | Method for increasing the concentration of conjugated linoleic acid in milk and/or tissue fat of a ruminant |
US5914346A (en) * | 1996-11-05 | 1999-06-22 | Wisconsin Alumni Research Foundation | Methods of treating animals to enhance natural killer lymphocyte function |
EP0954983A2 (en) * | 1998-05-04 | 1999-11-10 | ConLinCo, Inc. | Methods of using isomer enriched conjugated linoleic acid compositions |
US6060087A (en) * | 1997-04-25 | 2000-05-09 | Wisconsin Alumni Research Foundation | Method of increasing fat firmness and improving meat quality in animals |
US6177580B1 (en) | 1998-04-21 | 2001-01-23 | Henkel Kommanditgesellschaft Auf Aktien | Conjugated linolenic acid-based synthetic triglycerides |
US6479683B1 (en) | 2001-03-06 | 2002-11-12 | Ag Processing Inc | Process for conjugating fatty acid esters |
US6534110B1 (en) | 1995-11-14 | 2003-03-18 | Loders Croklaan B. V. | Process for the preparation of materials with a high content of long chain polyunsaturated fatty acids |
WO2004047551A1 (en) * | 2002-10-31 | 2004-06-10 | Piotr Zajac | Feed additive and process for manufacturing thereof |
US6762313B2 (en) | 2000-09-18 | 2004-07-13 | Cognis Deutschland Gmbh & Co. Kg | Processes for preparing linoleic acid raw materials for subsequent conjugation |
EP1468614A1 (en) * | 1996-07-22 | 2004-10-20 | Wisconsin Alumni Research Foundation | Method of improving the growth or the efficiency of feed conversion of an animal and composition for use therein |
US6881854B2 (en) | 2001-03-29 | 2005-04-19 | Basf Aktiengesellschaft | Conjugated unsaturated glyceride mixtures and a method for producing the same |
US7223543B2 (en) | 2001-06-08 | 2007-05-29 | Teagasc Dairy Products Research Centre | Conjugated linoleic acid isomerase and a process for the production of conjugated linoleic acid |
WO2007074010A1 (en) | 2005-12-24 | 2007-07-05 | Teagasc Dairy Products Research Centre | Process for the production of trans-10, cis 12 octadecadienoic acid |
US7304089B2 (en) | 2001-01-17 | 2007-12-04 | Basf Aktiengesellschaft | Preparation for improved dietary utilisation |
US7700833B2 (en) | 2002-03-01 | 2010-04-20 | Cornell University | Process for the production of unsaturated fatty acids |
US20150164966A1 (en) * | 2012-05-14 | 2015-06-18 | Hankkija Oy | Saponified tall oil fatty acid for use in treatment and animal feed supplements and compositions |
US9789143B2 (en) | 2013-05-14 | 2017-10-17 | Hankkija Oy | Use of tall oil fatty acid |
US9962353B2 (en) | 2013-10-24 | 2018-05-08 | Hankkija Oy | Use of tall oil fatty acid in binding toxins |
US10799544B2 (en) | 2013-11-13 | 2020-10-13 | Hankkija Oy | Feed supplement and a feed composition comprising resin acid based composition |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5674901A (en) * | 1995-06-01 | 1997-10-07 | Wisconsin Alumni Research Foundation | Methods of treating animals to maintain or increase CD-4 and CD-8 cell populations |
US5760082C1 (en) * | 1994-08-29 | 2001-03-06 | Wisconsin Alumni Res Found | Dietetic foods containing conjugated linoleic acids |
US5856149A (en) * | 1995-06-01 | 1999-01-05 | Wisconsin Alumni Research Foundation | Method of producing conjugated fatty acids |
US5756469A (en) * | 1996-07-26 | 1998-05-26 | Beale; Paxton K. | Composition of pyruvate and anti-cortisol compounds and method for increasing protein concentration in a mammal |
US5716926A (en) * | 1996-07-26 | 1998-02-10 | Paxton K. Beale | Composition of pyruvate and protein and method for increasing protein concentration in a mammal |
US5804210A (en) * | 1996-08-07 | 1998-09-08 | Wisconsin Alumni Research Foundation | Methods of treating animals to maintain or enhance bone mineral content and compositions for use therein |
US5837733A (en) * | 1997-02-26 | 1998-11-17 | Wisconsin Alumni Research Foundation | Method for reducing secetion of apolipoprotein B in animals by administering conjugated linoleic acid |
US5885594A (en) * | 1997-03-27 | 1999-03-23 | The Procter & Gamble Company | Oral compositions having enhanced mouth-feel |
AU1911999A (en) * | 1997-12-12 | 1999-06-28 | Penn State Research Foundation, The | Methods and compositions for treating diabetes |
US7015249B1 (en) | 1997-12-12 | 2006-03-21 | Purdue Research Foundation | Methods and compositions for treating diabetes |
JPH11209279A (en) * | 1998-01-05 | 1999-08-03 | Natural Ltd As | Method for decreasing body weight and treating obesity |
US6042869A (en) * | 1998-02-20 | 2000-03-28 | Natural Nutrition Ltd. | Bulk animal feeds containing conjugated linoleic acid |
US6020377A (en) * | 1998-03-13 | 2000-02-01 | Kansas State University Research Foundation | Modified tall oil supplemented diet for growing-finishing pigs |
US7078051B1 (en) * | 1998-08-11 | 2006-07-18 | Natural Asa | Conjugated linoleic acid alkyl esters in feedstuffs and food |
ATE350028T1 (en) | 1998-03-17 | 2007-01-15 | Natural Asa | CONJUGATED LINOLIC ACID COMPOSITION |
US7776353B1 (en) | 1998-03-17 | 2010-08-17 | Aker Biomarine Asa | Conjugated linoleic acid compositions |
US6015833A (en) | 1998-03-17 | 2000-01-18 | Conlinco., Inc. | Conjugated linoleic acid compositions |
US6077525A (en) * | 1998-04-10 | 2000-06-20 | The George Washington University | Use of conjugated linoleic acids |
US6113973A (en) * | 1998-04-15 | 2000-09-05 | Wisconsin Alumni Research Foundation | Eggs enriched with conjugated linoleic acid |
US7101914B2 (en) * | 1998-05-04 | 2006-09-05 | Natural Asa | Isomer enriched conjugated linoleic acid compositions |
US6060514A (en) * | 1998-05-04 | 2000-05-09 | Conlin Co., Inc. | Isomer enriched conjugated linoleic acid compositions |
US6214372B1 (en) | 1998-05-04 | 2001-04-10 | Con Lin Co., Inc. | Method of using isomer enriched conjugated linoleic acid compositions |
US6696584B2 (en) | 1998-05-04 | 2004-02-24 | Natural Asa | Isomer enriched conjugated linoleic acid compositions |
CA2334044C (en) * | 1998-08-20 | 2014-03-25 | E.I. Du Pont De Nemours And Company | Genes for plant fatty acid modifying enzymes associated with conjugated double bond formation |
US6413545B1 (en) | 1998-09-01 | 2002-07-02 | Access Business Group International Llc | Diet composition and method of weight management |
US6440931B1 (en) | 1999-02-23 | 2002-08-27 | Natural Corporation | Conjugated linoleic acid in treatment and prophylaxis of diabetes |
US6020378A (en) * | 1999-03-30 | 2000-02-01 | Wisconsin Alumni Research Foundation | Method for selectively altering body fat level, feed efficiently, or weight gain |
US6077868A (en) * | 1999-07-20 | 2000-06-20 | Wisconsin Alumni Research Foundation | Selective inhibition of cyclooxygenase-2 |
JP2003507041A (en) * | 1999-08-16 | 2003-02-25 | イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー | Process for producing calendic acid, fatty acids containing delta-8,10,12 conjugated double bonds and related fatty acids having a modification at the delta-9 position |
US7947737B1 (en) | 1999-09-30 | 2011-05-24 | Aker Biomarine Asa | Method of treating hypertension and reducing serum lipase activity |
US6420577B1 (en) | 1999-12-01 | 2002-07-16 | Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Agriculture | Method for commercial preparation of conjugated linoleic acid |
KR20020075775A (en) * | 1999-12-16 | 2002-10-05 | 시스킨드, 해리 | Nutritional Composition, Methods of Producing Said Composition and Methods of Using Said Composition |
CZ20022507A3 (en) * | 2000-01-20 | 2003-01-15 | Omegatech, Inc. | Method for breeding rabbits |
US6432469B1 (en) | 2000-02-17 | 2002-08-13 | Natural Corporation | Bulk animal feeds containing conjugated linoleic acid |
CA2404799C (en) * | 2000-04-06 | 2007-08-07 | Conlinco, Inc. | Conjugated linoleic acid compositions |
US20030149288A1 (en) * | 2000-04-18 | 2003-08-07 | Natural Asa | Conjugated linoleic acid powder |
EP1274320A2 (en) | 2000-04-18 | 2003-01-15 | Natural AS | Conjugated linoleic acid powder |
KR20020017482A (en) * | 2000-08-30 | 2002-03-07 | 정병현 | Immunoglobulin reinforcing composition |
US6809115B2 (en) | 2000-09-21 | 2004-10-26 | Nutrition 21, Inc. | Methods and compositions for the treatment of diabetes, the reduction of body fat, improvement of insulin sensitivity, reduction of hyperglycemia, and reduction of hypercholesterolemia with chromium complexes, conjugated fatty acids, and/or conjugated fatty alcohols |
US6395782B1 (en) | 2001-03-02 | 2002-05-28 | Wisconsin Alumni Research Foundation | Method of increasing longevity and preventing body weight wasting in autoimmune disease by using conjugated linoleic acid |
US6677470B2 (en) | 2001-11-20 | 2004-01-13 | Natural Asa | Functional acylglycerides |
US6414171B1 (en) | 2001-11-27 | 2002-07-02 | Her Majesty In Right Of Canada, As Represented By The Minister Of Agriculture & Agri-Food Canada | Method for commercial preparation of conjugated linoleic acid from by-products of vegetable oil refining |
US6409649B1 (en) | 2001-11-27 | 2002-06-25 | Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Agriculture & Agri-Food Canada | Method for commercial preparation of conjugated linoleic acid using recycled alkali transesterification catalyst |
EP1545464B1 (en) * | 2002-08-01 | 2020-09-02 | The Regents of The University of California | Method and compositions for preparing and delivering rumen protected lipids, other nutrients and medicaments |
US20050186282A1 (en) * | 2002-08-01 | 2005-08-25 | The Regents Of The University Of California, A California Corporation | Method and compositions for preparing and delivering lipids, other nutrients and medicaments |
CA2396840A1 (en) * | 2002-08-06 | 2004-02-06 | Juan Miguel Garro Galvez | New conjugated linolenic acids and methods for commercial preparation, purification and uses |
US6743931B2 (en) | 2002-09-24 | 2004-06-01 | Natural Asa | Conjugated linoleic acid compositions |
US6897327B2 (en) * | 2003-05-08 | 2005-05-24 | Stepan Company | Manufacture of conjugated linoleic salts and acids |
CA2436650A1 (en) * | 2003-08-06 | 2005-02-06 | Naturia Inc. | Conjugated linolenic acid (clnatm) compositions: synthesis, purification and uses |
US20070191619A1 (en) * | 2003-12-23 | 2007-08-16 | Stepan Company | Production and purification of esters of conjugated linoleic acids |
DE102004043824A1 (en) * | 2004-09-10 | 2006-03-16 | Cognis Ip Management Gmbh | Emulsions with unsaturated fatty acids and their esters |
US20060182785A1 (en) * | 2005-02-17 | 2006-08-17 | Peterson Daniel G | System and method for producing foie gras in poultry |
EP1957063B1 (en) * | 2005-12-05 | 2010-08-25 | Stepan Company | Process for preparing conjugated linoleic acid and derivatives thereof from ricinoleic acid |
DE102007009650A1 (en) * | 2007-02-26 | 2008-08-28 | Beiersdorf Ag | Cosmetic combination product to improve the external appearance |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4603142A (en) * | 1984-06-01 | 1986-07-29 | Wisconsin Alumni Research Foundation | Cholesterol lowering method of use |
JPS61294982A (en) * | 1985-06-22 | 1986-12-25 | Csk Corp | Communication system for character information in catv |
JPS6398355A (en) * | 1986-10-16 | 1988-04-28 | Kazumitsu Maruta | Feed for animal |
US5017614A (en) * | 1989-02-17 | 1991-05-21 | Wisconsin Alumni Research Foundation | Methods of preventing oxidation, quenching singlet oxygen and inhibiting mold growth and novel compositions therefor |
US5070104A (en) * | 1989-02-17 | 1991-12-03 | Wisconsin Alumni Research Foundation | Methods of chelating metal and novel compositions therefor |
US5162337A (en) * | 1990-10-05 | 1992-11-10 | Merck & Co., Inc. | Animal growth promotion |
US5430066A (en) * | 1992-04-29 | 1995-07-04 | Wisconsin Alumni Research Foundation | Methods for preventing weight loss, reduction in weight gain, and anorexia due to immune stimulation |
-
1993
- 1993-01-22 US US08/007,413 patent/US5428072A/en not_active Expired - Lifetime
- 1993-11-16 WO PCT/US1993/011093 patent/WO1994016690A1/en active IP Right Grant
- 1993-11-16 JP JP6516993A patent/JP2745245B2/en not_active Expired - Lifetime
- 1993-11-16 DE DE69328497T patent/DE69328497T2/en not_active Expired - Lifetime
- 1993-11-16 EP EP94902262A patent/EP0680318B1/en not_active Expired - Lifetime
Non-Patent Citations (1)
Title |
---|
O.H. SIEGMUND et al., "The Merck Veterinary Manual", published 1979 by Merck & Co. (NJ), see pages 1340-1343, 1374-1379. * |
Cited By (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5554646A (en) * | 1992-04-29 | 1996-09-10 | Wisconsin Alumni Research Foundation | Method for reducing body fat in animals |
WO1996006605A1 (en) * | 1994-08-29 | 1996-03-07 | Wisconsin Alumni Research Foundation | Method of reducing body fat in animals by the administration of conjugated linoleic acid |
EP0779033A1 (en) * | 1995-11-14 | 1997-06-18 | Unilever N.V. | Edible fat-spread |
US6534110B1 (en) | 1995-11-14 | 2003-03-18 | Loders Croklaan B. V. | Process for the preparation of materials with a high content of long chain polyunsaturated fatty acids |
US6159525A (en) * | 1995-11-14 | 2000-12-12 | Van Den Bergh Foods Co., Division Of Conopco, Inc. | Edible fat-spread |
EP1438898A3 (en) * | 1996-06-07 | 2005-01-05 | Wisconsin Alumni Research Foundation | Method for maintaining an existing level of body fat and/or body weight |
WO1997046230A1 (en) * | 1996-06-07 | 1997-12-11 | Wisconsin Alumni Research Foundation | Method for maintaining an existing level of body fat and/or body weight |
EP1438898A2 (en) * | 1996-06-07 | 2004-07-21 | Wisconsin Alumni Research Foundation | Method for maintaining an existing level of body fat and/or body weight |
EP1468614A1 (en) * | 1996-07-22 | 2004-10-20 | Wisconsin Alumni Research Foundation | Method of improving the growth or the efficiency of feed conversion of an animal and composition for use therein |
WO1998005319A1 (en) * | 1996-08-07 | 1998-02-12 | Wisconsin Alumni Research Foundation | Methods of preventing skeletal problems in poultry |
US5914346A (en) * | 1996-11-05 | 1999-06-22 | Wisconsin Alumni Research Foundation | Methods of treating animals to enhance natural killer lymphocyte function |
US6060087A (en) * | 1997-04-25 | 2000-05-09 | Wisconsin Alumni Research Foundation | Method of increasing fat firmness and improving meat quality in animals |
US5851572A (en) * | 1997-04-25 | 1998-12-22 | Wisconsin Alumni Research Foundation | Method of increasing fat firmness and improving meat quality in animals with conjugated linolenic acid |
DE19718245C1 (en) * | 1997-04-30 | 1998-07-30 | Henkel Kgaa | Synthetic tri:glyceride(s) useful as food additives |
DE19718245C5 (en) * | 1997-04-30 | 2004-11-11 | Cognis Deutschland Gmbh & Co. Kg | Synthetic triglycerides based on conjugated linoleic acid, process for their preparation and their use |
US6468556B1 (en) | 1997-09-05 | 2002-10-22 | Otsuka Pharmaceutical Co., Ltd. | Liver fat accumulation inhibitory composition, food additive for liver fat accumulation, inhibition, and method of inhibiting liver fat accumulation |
WO1999012538A1 (en) * | 1997-09-05 | 1999-03-18 | Otsuka Pharmaceutical Co., Ltd. | Liver fat accumulation inhibitory composition, food additive for liver fat accumulation inhibition, and method of inhibiting liver fat accumulation |
BG64498B1 (en) * | 1997-10-21 | 2005-05-31 | Valio Oy | Method for increasing the concentration of conjugated linoleic acid in milk and/or tissue fat of a ruminant, the use of trans-11 isomer of octadecenoic acid for increasing the concentration of conjugated linoleic acid in lactic and/or tissue fat of ruminants and composition of animal feed |
WO1999020123A1 (en) * | 1997-10-21 | 1999-04-29 | Valio Oy | Method for increasing the concentration of conjugated linoleic acid in milk and/or tissue fat of a ruminant |
US6635271B1 (en) | 1997-10-21 | 2003-10-21 | Valio Oy | Method for increasing the concentration of conjugated linoleic acid in milk and/or tissue fat of a ruminant |
US6177580B1 (en) | 1998-04-21 | 2001-01-23 | Henkel Kommanditgesellschaft Auf Aktien | Conjugated linolenic acid-based synthetic triglycerides |
EP0954983A2 (en) * | 1998-05-04 | 1999-11-10 | ConLinCo, Inc. | Methods of using isomer enriched conjugated linoleic acid compositions |
EP0954983A3 (en) * | 1998-05-04 | 2001-06-13 | ConLinCo, Inc. | Methods of using isomer enriched conjugated linoleic acid compositions |
EP0954975A3 (en) * | 1998-05-04 | 2001-06-13 | ConLinCo, Inc. | Isomer enriched conjugated linoleic acid compositions |
EP0954975A2 (en) * | 1998-05-04 | 1999-11-10 | ConLinCo, Inc. | Isomer enriched conjugated linoleic acid compositions |
US6762313B2 (en) | 2000-09-18 | 2004-07-13 | Cognis Deutschland Gmbh & Co. Kg | Processes for preparing linoleic acid raw materials for subsequent conjugation |
US7304089B2 (en) | 2001-01-17 | 2007-12-04 | Basf Aktiengesellschaft | Preparation for improved dietary utilisation |
US6479683B1 (en) | 2001-03-06 | 2002-11-12 | Ag Processing Inc | Process for conjugating fatty acid esters |
US6881854B2 (en) | 2001-03-29 | 2005-04-19 | Basf Aktiengesellschaft | Conjugated unsaturated glyceride mixtures and a method for producing the same |
US7223543B2 (en) | 2001-06-08 | 2007-05-29 | Teagasc Dairy Products Research Centre | Conjugated linoleic acid isomerase and a process for the production of conjugated linoleic acid |
US7700833B2 (en) | 2002-03-01 | 2010-04-20 | Cornell University | Process for the production of unsaturated fatty acids |
WO2004047551A1 (en) * | 2002-10-31 | 2004-06-10 | Piotr Zajac | Feed additive and process for manufacturing thereof |
WO2007074010A1 (en) | 2005-12-24 | 2007-07-05 | Teagasc Dairy Products Research Centre | Process for the production of trans-10, cis 12 octadecadienoic acid |
US20150164966A1 (en) * | 2012-05-14 | 2015-06-18 | Hankkija Oy | Saponified tall oil fatty acid for use in treatment and animal feed supplements and compositions |
US9789077B2 (en) | 2012-05-14 | 2017-10-17 | Hankkija Oy | Use of saponified tall oil fatty acid |
US9907771B2 (en) | 2012-05-14 | 2018-03-06 | Hankkija Oy | Saponified tall oil fatty acid for use in treatment and animal feed supplements and compositions |
US9789143B2 (en) | 2013-05-14 | 2017-10-17 | Hankkija Oy | Use of tall oil fatty acid |
US9919013B2 (en) | 2013-05-14 | 2018-03-20 | Hankkija Oy | Use of tall oil fatty acid |
US10092610B2 (en) | 2013-05-14 | 2018-10-09 | Hankkija Oy | Tall oil fatty acid for use in treatment and animal feed supplements and compositions |
US9962353B2 (en) | 2013-10-24 | 2018-05-08 | Hankkija Oy | Use of tall oil fatty acid in binding toxins |
US10799544B2 (en) | 2013-11-13 | 2020-10-13 | Hankkija Oy | Feed supplement and a feed composition comprising resin acid based composition |
US10849947B2 (en) | 2013-11-13 | 2020-12-01 | Hankkija Oy | Feed supplement and a feed composition comprising resin acid based composition |
US11253562B2 (en) | 2013-11-13 | 2022-02-22 | Forchem Oy | Feed supplement |
Also Published As
Publication number | Publication date |
---|---|
JP2745245B2 (en) | 1998-04-28 |
EP0680318A1 (en) | 1995-11-08 |
EP0680318A4 (en) | 1995-09-12 |
JPH08505775A (en) | 1996-06-25 |
DE69328497T2 (en) | 2001-01-04 |
US5428072A (en) | 1995-06-27 |
EP0680318B1 (en) | 2000-04-26 |
DE69328497D1 (en) | 2000-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5428072A (en) | Method of increasing the efficiency of feed conversion in animals | |
EP0579901B1 (en) | Use of a feed additive for preventing weight loss, reduction in weight gain, and anorexia due to immune stimulation | |
EP0831804B1 (en) | Methods for maintaining or elevating the cd-4 or cd-8 cell levels comprising the administration of conjugated linoleic acid; a new process for the manufacture of conjugated linoleic acid using lactobacillus sp | |
EP0731699B1 (en) | Method of reducing body fat in animals by the administration of conjugated linoleic acid | |
EP0907360B1 (en) | Method for maintaining an existing level of body fat and/or body weight | |
EP0918516B1 (en) | Methods of preventing skeletal problems in poultry | |
EP0920309B1 (en) | Conjugated linoleic acid to maintain or enhance bone mineral content | |
AU771921B2 (en) | Method for selectively altering body fat level, feed efficiency, or weight gain | |
CA2267109C (en) | Use of conjugated linoleic acid to enhance natural killer lymphocyte function | |
KR940007396B1 (en) | Omega-egg and omega-meat, method and assorted feed for producing them | |
JPH0531527B2 (en) | ||
GB2057873A (en) | Animal feeds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1994902262 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1994902262 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1994902262 Country of ref document: EP |